Moreover, a study demonstrated that the use of antiangiogenic therapy in breast cancer upregulated the expression of PD-L1 on the surfaces of ECs and tumor cells and increased the sensitivity with anti-PD-1 therapy [88]. Here, CD274 is linked to breast carcinoma.